Developer docs
API playgroundTry for free, no card

Search company profiles

i2020 Accelerator

Full company profile

uuid0003yz3

Namestring
i2020 Accelerator
Legal namestring
T123 LLC
Company typeenum
Private
Founded yearint
2017
Descriptiontext

i2020 Accelerator is a drug discovery accelerator that co-creates early-stage biotechnology companies in four therapeutic areas: inflammation, oncology, central nervous system disorders, and infectious diseases. Inaugurated in 2017 and launched in January 2018 with up to $30 million of backing from Torrey Pines Investment, the firm takes majority equity positions in newly created portfolio entities and operates a two-year acceleration model intended to move programs from concept to a value-creating milestone before exit or further financing. The company serves emerging biotech founders and scientific entrepreneurs by providing capital, infrastructure, and operational support rather than selling products directly to end customers.

The company's core technology infrastructure is the Loch platform, which integrates computational drug design, screening, and chemistry workflows. i2020 delivers these capabilities through technology partnerships rather than purely internal build — most notably with Molsoft LLC for AI-driven molecular modeling, computer-aided drug design, and giga-screening, and with ChemDiv Inc. for chemistry and compound library access. By 2023, the platform supported 14+ portfolio companies, with cumulative funding across those companies exceeding $100 million, and the company has stated an ambition to launch 20–30 drug discovery programs over its operating horizon.

Commercially, i2020 generates returns primarily through equity appreciation in portfolio companies, supplemented by co-investment capital from partners such as OrbiMed and BioGeneration Ventures. The firm operates from three offices — San Diego (headquarters), Cambridge, Massachusetts, and Basel, Switzerland — and is legally organized as T123 LLC. In 2023, i2020 was integrated into the Expert Systems integrated accelerator platform, consolidating it with related investment vehicles under a broader portfolio strategy. Revenue is not publicly disclosed, and the business model is therefore best characterized as a fund-like accelerator with capital-intensive, exit-driven return mechanics.

Short descriptiontext

i2020 Accelerator is a drug discovery accelerator that co-creates biotech programs in inflammation, oncology, CNS, and infectious diseases, using its Loch platform and AI/computational partnerships to support 14+ portfolio companies across San Diego, Cambridge, and Basel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery accelerator, early-stage biotech investing, oncology discovery programs, AI drug design platform, venture-backed biotech incubation
Industry2 codes
PRIMARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Investment Advice6282
  • Services-Commercial Physical & Biological Research8731
Product category
Biotech Accelerator / Drug Discovery Investment Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Accelerator Program Returns
TypeLicensing Royalties
Description

As an accelerator backed by Torrey Pines Investment, i2020 generates returns through equity stakes and co-development agreements with portfolio companies. The accelerator takes equity in early-stage drug discovery programs and earns returns upon successful development milestones or exit events.

i2020accelerator.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

i2020 Accelerator is a drug discovery accelerator that provides seed funding, R&D expertise, and access to a global scientific network to co-create early-stage small-molecule drug discovery programs with biotech startups. The accelerator takes equity stakes in selected programs and drives them toward advanced lead and clinical candidate stage within a two-year framework, with a planned portfolio of 20-30 diverse programs across oncology, immunology, inflammation, CNS, and infectious diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Accelerates drug discovery programs to advanced lead and clinical candidate level within two-year timeframe
+1 more record
Product overview1 text field

i2020 Accelerator is a drug discovery accelerator program that does not offer a standalone software product. Instead, it operates as an investment and partnership vehicle that accelerates early-stage drug discovery programs through funding, scientific expertise, and access to a global resource network. The core service involves co-creating drug discovery programs with biotech companies, helping them advance from early research to advanced lead compounds and clinical candidates within a two-year timeframe. The company partners with research organizations (Molsoft LLC for AI and computer-aided drug design, ChemDiv Inc. for drug discovery solutions) to support portfolio companies developing treatments across oncology, immunology, infectious diseases, CNS/neurology, inflammation, and autoimmune diseases. Key portfolio programs include the Loch platform (multiple oncology-focused companies), as well as investments in companies like Stelvio Therapeutics (epigenetic platform for glioblastoma), Snap Bio (selective kinase inhibitors), Eilean Therapeutics (hematological cancers), and Trawsfynydd Therapeutics (virology).

Product and service2 records
1i2020 Accelerator Program
CategoryBiotech Accelerator / Drug Discovery Investment
Description

Drug discovery accelerator program that provides seed funding, R&D expertise, and access to a global scientific network to co-create early-stage small-molecule drug discovery programs with biotech startups, with a target of 20-30 diverse drug discovery programs.

2Loch Platform
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Consulting platform for drug discovery and development program selection, prioritization, design, execution and market positioning. Offers highly customized solutions for pharma and biotech in oncology, inflammation, immunology, cardiometabolic, neurology and infectious disease therapeutic areas. i2020 is part of the Expert Systems integrated accelerator platform.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Third largest university in Finland with 25,000 students and personnel. i2020 invested in a cutting-edge research program studying previously unrecognized protein-protein interactions that disrupt NMDA receptor signaling pathways for neurodegenerative conditions and neuropathic pain. ChemDiv provides scientific expertise as part of the collaboration.

Strategic tierCoreTypeTechnology or Integration
Description

Leading provider of tools, databases and consulting services in structure prediction, structural proteomics, bioinformatics, cheminformatics, molecular visualization and animation, and rational drug design. Provides AI and computer-aided drug design platform supporting the Loch platform and its programs.

Strategic tierCoreTypeTechnology or Integration
Description

Recognized global leader in drug discovery solutions with over 29 years of experience. Delivered hundreds of leads, drug candidates and new drugs in CNS, oncology, virology, inflammation, cardiometabolic and immunology. Provides integrated drug discovery platform and risk-share collaborative platforms for i2020 portfolio companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

OrbiMed is a $19B+ AUM healthcare investment firm that co-invests in i2020's portfolio companies (Loch platform, Trawsfynydd, Brenig). As i2020's most significant financial partner, OrbiMed is structurally comparable but operates at a much larger scale across all stages of healthcare investing, not purely accelerator creation.

TypeBroad incumbent
Description

RA Capital is a crossover healthcare investor with both early-stage creation activities and late-stage public/private investments. While i2020 focuses exclusively on early-stage creation, RA Capital's TechAtlas and creation-focused funds represent a broader incumbent in the same biotech acceleration ecosystem.

TypeBroad incumbent
Description

BridgeBio is a clinical-stage biotech company that originated from a venture creation model similar in spirit to i2020's accelerator framework. While BridgeBio has progressed to a commercial-stage operating company, its origin as a multi-program creation engine makes it a useful comparable for the platform approach i2020 employs across the Loch platform.

TypeDirect peer
Description

Atlas Venture builds biotech companies from inception through a "venture creation" model with a strong focus on early-stage drug discovery and platform technologies. Both i2020 and Atlas follow a similar playbook of seed-creation-stage investments in therapeutic programs with co-investor syndicates.

TypeDirect peer
Description

ARCH Venture Partners is a deep-tech and biotech-focused VC that creates and funds early-stage life sciences companies, often co-founding them with academic founders. ARCH shares i2020's model of building companies around novel science in partnership with co-investors and operating partners.

TypeDirect peer
Description

Apple Tree Partners is a healthcare-focused venture firm that builds biotech companies from the ground up with dedicated scientific and operating teams. Both ATP and i2020 follow a company-creation approach, often co-founding therapeutic startups with internal R&D capabilities before partnering with larger investors.

TypeDirect peer
Description

SV Health Investors is a transatlantic healthcare VC that builds biotech companies via its Dementia Discovery Fund and other specialized vehicles. Like i2020, SV focuses on first-in-class therapeutics in high-unmet-need areas (neurology, oncology) and uses a creation-driven model with co-investor syndicates.

TypeDirect peer
Description

Flagship Pioneering is a bioplatform company that creates and develops first-in-class biotech companies, most notably Moderna. Like i2020, it operates a creation engine model that builds companies around breakthrough science and partners with major investors, making it the closest direct comparable in the biotech accelerator space.

TypeDirect peer
Description

BGV is a European early-stage biotech VC that co-invests with i2020 and OrbiMed (e.g., Brenig Therapeutics). It operates a similar creation-focused model targeting first-in-class European biotech, making it both a partner and a structural peer in the early-stage European biotech accelerator segment.

TypeDirect peer
Description

Petri is a biotech creation platform backed by Section32 that builds early-stage companies around breakthrough science. It operates as a direct accelerator-style peer to i2020, with similar emphasis on first-in-class biology and therapeutic area breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

i2020 Accelerator

Biotech Accelerator / Drug Discovery Investment Servicesi2020accelerator.com

i2020 Accelerator is a drug discovery accelerator that co-creates biotech programs in inflammation, oncology, CNS, and infectious diseases, using its Loch platform and AI/computational partnerships to support 14+ portfolio companies across San Diego, Cambridge, and Basel.

What i2020 Accelerator does

i2020 Accelerator is a drug discovery accelerator that co-creates early-stage biotechnology companies in four therapeutic areas: inflammation, oncology, central nervous system disorders, and infectious diseases. Inaugurated in 2017 and launched in January 2018 with up to $30 million of backing from Torrey Pines Investment, the firm takes majority equity positions in newly created portfolio entities and operates a two-year acceleration model intended to move programs from concept to a value-creating milestone before exit or further financing. The company serves emerging biotech founders and scientific entrepreneurs by providing capital, infrastructure, and operational support rather than selling products directly to end customers.

The company's core technology infrastructure is the Loch platform, which integrates computational drug design, screening, and chemistry workflows. i2020 delivers these capabilities through technology partnerships rather than purely internal build — most notably with Molsoft LLC for AI-driven molecular modeling, computer-aided drug design, and giga-screening, and with ChemDiv Inc. for chemistry and compound library access. By 2023, the platform supported 14+ portfolio companies, with cumulative funding across those companies exceeding $100 million, and the company has stated an ambition to launch 20–30 drug discovery programs over its operating horizon.

Commercially, i2020 generates returns primarily through equity appreciation in portfolio companies, supplemented by co-investment capital from partners such as OrbiMed and BioGeneration Ventures. The firm operates from three offices — San Diego (headquarters), Cambridge, Massachusetts, and Basel, Switzerland — and is legally organized as T123 LLC. In 2023, i2020 was integrated into the Expert Systems integrated accelerator platform, consolidating it with related investment vehicles under a broader portfolio strategy. Revenue is not publicly disclosed, and the business model is therefore best characterized as a fund-like accelerator with capital-intensive, exit-driven return mechanics.

i2020 Accelerator firmographics

Firmographics
Name
i2020 Accelerator
Legal name
T123 LLC
Website
https://i2020accelerator.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
i2020 Accelerator is a drug discovery accelerator that co-creates biotech programs in inflammation, oncology, CNS, and infectious diseases, using its Loch platform and AI/computational partnerships to support 14+ portfolio companies across San Diego, Cambridge, and Basel.
Ownership category
akta.pro rank

i2020 Accelerator industry classification

Industry
Product category
Biotech Accelerator / Drug Discovery Investment Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug discovery accelerator
  • Early-stage biotech investing
  • Oncology discovery programs
  • AI drug design platform
  • Venture-backed biotech incubation

Where i2020 Accelerator is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

i2020 Accelerator business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Accelerator Program Returns: As an accelerator backed by Torrey Pines Investment, i2020 generates returns through equity stakes and co-development agreements with portfolio companies. The accelerator takes equity in early-stage drug discovery programs and earns returns upon successful development milestones or exit events.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

i2020 Accelerator product offering

Product offering

Core offering

i2020 Accelerator is a drug discovery accelerator that provides seed funding, R&D expertise, and access to a global scientific network to co-create early-stage small-molecule drug discovery programs with biotech startups. The accelerator takes equity stakes in selected programs and drives them toward advanced lead and clinical candidate stage within a two-year framework, with a planned portfolio of 20-30 diverse programs across oncology, immunology, inflammation, CNS, and infectious diseases.

Product overview

i2020 Accelerator is a drug discovery accelerator program that does not offer a standalone software product. Instead, it operates as an investment and partnership vehicle that accelerates early-stage drug discovery programs through funding, scientific expertise, and access to a global resource network. The core service involves co-creating drug discovery programs with biotech companies, helping them advance from early research to advanced lead compounds and clinical candidates within a two-year timeframe. The company partners with research organizations (Molsoft LLC for AI and computer-aided drug design, ChemDiv Inc. for drug discovery solutions) to support portfolio companies developing treatments across oncology, immunology, infectious diseases, CNS/neurology, inflammation, and autoimmune diseases. Key portfolio programs include the Loch platform (multiple oncology-focused companies), as well as investments in companies like Stelvio Therapeutics (epigenetic platform for glioblastoma), Snap Bio (selective kinase inhibitors), Eilean Therapeutics (hematological cancers), and Trawsfynydd Therapeutics (virology).

Differentiator

Problem solved

Functional benefit

Products and services

  • i2020 Accelerator Program Drug discovery accelerator program that provides seed funding, R&D expertise, and access to a global scientific network to co-create early-stage small-molecule drug discovery programs with biotech startups, with a target of 20-30 diverse drug discovery programs.
  • Loch Platform

Quantifiable outcome

  • Accelerates drug discovery programs to advanced lead and clinical candidate level within two-year timeframe
  • +1 more outcomes

Companies that use i2020 Accelerator

Customer profile

Segments2 records

Ideal customer profiles2 records

i2020 Accelerator technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

i2020 Accelerator partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Expert Systems InccoreStrategic or Co-development Partner · 1 January 2023Consulting platform for drug discovery and development program selection, prioritization, design, execution and market positioning. Offers highly customized solutions for pharma and biotech in oncology, inflammation, immunology, cardiometabolic, neurology and infectious disease therapeutic areas. i2020 is part of the Expert Systems integrated accelerator platform.
  • University of Turku (UTU)majorStrategic or Co-development Partner · 1 January 2019Third largest university in Finland with 25,000 students and personnel. i2020 invested in a cutting-edge research program studying previously unrecognized protein-protein interactions that disrupt NMDA receptor signaling pathways for neurodegenerative conditions and neuropathic pain. ChemDiv provides scientific expertise as part of the collaboration.
  • Molsoft LLCcoreTechnology or IntegrationLeading provider of tools, databases and consulting services in structure prediction, structural proteomics, bioinformatics, cheminformatics, molecular visualization and animation, and rational drug design. Provides AI and computer-aided drug design platform supporting the Loch platform and its programs.
  • ChemDiv Inc.coreTechnology or IntegrationRecognized global leader in drug discovery solutions with over 29 years of experience. Delivered hundreds of leads, drug candidates and new drugs in CNS, oncology, virology, inflammation, cardiometabolic and immunology. Provides integrated drug discovery platform and risk-share collaborative platforms for i2020 portfolio companies.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

i2020 Accelerator competitors and assessment

Company assessment

Emerging players

  • OrbiMed Advisors: OrbiMed is a $19B+ AUM healthcare investment firm that co-invests in i2020's portfolio companies (Loch platform, Trawsfynydd, Brenig). As i2020's most significant financial partner, OrbiMed is structurally comparable but operates at a much larger scale across all stages of healthcare investing, not purely accelerator creation.

Broad incumbents

  • RA Capital Management: RA Capital is a crossover healthcare investor with both early-stage creation activities and late-stage public/private investments. While i2020 focuses exclusively on early-stage creation, RA Capital's TechAtlas and creation-focused funds represent a broader incumbent in the same biotech acceleration ecosystem.
  • BridgeBio Pharma: BridgeBio is a clinical-stage biotech company that originated from a venture creation model similar in spirit to i2020's accelerator framework. While BridgeBio has progressed to a commercial-stage operating company, its origin as a multi-program creation engine makes it a useful comparable for the platform approach i2020 employs across the Loch platform.

Direct peers

  • Atlas Venture: Atlas Venture builds biotech companies from inception through a "venture creation" model with a strong focus on early-stage drug discovery and platform technologies. Both i2020 and Atlas follow a similar playbook of seed-creation-stage investments in therapeutic programs with co-investor syndicates.
  • ARCH Venture Partners: ARCH Venture Partners is a deep-tech and biotech-focused VC that creates and funds early-stage life sciences companies, often co-founding them with academic founders. ARCH shares i2020's model of building companies around novel science in partnership with co-investors and operating partners.
  • Apple Tree Partners: Apple Tree Partners is a healthcare-focused venture firm that builds biotech companies from the ground up with dedicated scientific and operating teams. Both ATP and i2020 follow a company-creation approach, often co-founding therapeutic startups with internal R&D capabilities before partnering with larger investors.
  • SV Health Investors: SV Health Investors is a transatlantic healthcare VC that builds biotech companies via its Dementia Discovery Fund and other specialized vehicles. Like i2020, SV focuses on first-in-class therapeutics in high-unmet-need areas (neurology, oncology) and uses a creation-driven model with co-investor syndicates.
  • Flagship Pioneering: Flagship Pioneering is a bioplatform company that creates and develops first-in-class biotech companies, most notably Moderna. Like i2020, it operates a creation engine model that builds companies around breakthrough science and partners with major investors, making it the closest direct comparable in the biotech accelerator space.
  • BioGeneration Ventures (BGV): BGV is a European early-stage biotech VC that co-invests with i2020 and OrbiMed (e.g., Brenig Therapeutics). It operates a similar creation-focused model targeting first-in-class European biotech, making it both a partner and a structural peer in the early-stage European biotech accelerator segment.
  • Petri Bio: Petri is a biotech creation platform backed by Section32 that builds early-stage companies around breakthrough science. It operates as a direct accelerator-style peer to i2020, with similar emphasis on first-in-class biology and therapeutic area breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

i2020 Accelerator social profiles

Digital presence

i2020 Accelerator financial estimates

Financial estimate

Revenue estimate

Valuation estimate

i2020 Accelerator leadership team

Management profile

Number of profiles

Profiles2 records

i2020 Accelerator funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

i2020 Accelerator M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about i2020 Accelerator

What does i2020 Accelerator do?

i2020 Accelerator is a drug discovery accelerator that provides seed funding, R&D expertise, and access to a global scientific network to co-create early-stage small-molecule drug discovery programs with biotech startups. The accelerator takes equity stakes in selected programs and drives them toward advanced lead and clinical candidate stage within a two-year framework, with a planned portfolio of 20-30 diverse programs across oncology, immunology, inflammation, CNS, and infectious diseases.

Is i2020 Accelerator a public or private company?

i2020 Accelerator is a private company. It is classified as venture growth investor backed and is currently operating.

When was i2020 Accelerator founded?

i2020 Accelerator was founded in 2017. It employs 1 to 10 people.

Where is i2020 Accelerator based?

i2020 Accelerator is headquartered in San Diego, United States, in the North America region.

How does i2020 Accelerator make money?

One revenue line is on record: accelerator Program Returns.

Who are i2020 Accelerator's main competitors?

OrbiMed Advisors is listed as an emerging player. Broad incumbents are RA Capital Management and BridgeBio Pharma. Direct peers are Atlas Venture, ARCH Venture Partners, Apple Tree Partners, SV Health Investors, Flagship Pioneering, BioGeneration Ventures (BGV) and Petri Bio.

Does i2020 Accelerator have an API?

No public API is recorded for i2020 Accelerator.

What industry is i2020 Accelerator in?

i2020 Accelerator's product category is Biotech Accelerator / Drug Discovery Investment Services. Its primary akta.pro industry code is FSANAAAM, Accelerators & Incubators (Investor-Operated), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswirei2020 Accelerator Announces the Launch of Gwynant Therapeutics and Celyn Therapeutics to Develop Novel Small Molecules for Oncology Targetsi2020 Accelerator, backed by San Diego-based Torrey Pines Investment, announced two new oncology-focused start-up investments in partnership with OrbiMed Advisors, launching Gwynant Therapeutics and Celyn Therapeutics. The new investment brings total funding for 9 companies in the Loch platform to over $68.5 million, with proceeds directed toward developing proprietary small molecule cancer treatments. Carl Gordon and Iain Dukes from OrbiMed, Nikolay Savchuk from Torrey Pines Investment, and Augustine Lawlor from Health Care Ventures have joined the boards of both new companies.PR Newswirei2020 Accelerator Announces New Investments in Cancer-, Inflammation- and Neurology-focused Therapeuticsi2020 Accelerator, backed by Torrey Pines Investment, announced multiple investment rounds together with OrbiMed and BioGeneration Ventures, deploying follow-on capital to three oncology companies and seed funding to five new startups focused on oncology, inflammation, and neurology. The total funding for the seven portfolio companies reached $52 million, with an additional $8 million allocated to the European venture Brenig Therapeutics. The investments support the Loch platform, which aims to develop novel targeted treatments for cancer, immunological, and neurodegenerative diseases using AI and computer-aided drug design.PR Newswirei2020 Accelerator of Torrey Pines Investment in Breakthrough Cancer Programs together with OrbiMedi2020 Accelerator, backed by Torrey Pines Investment, has announced an up to $28.5 million seed investment co-led with OrbiMed in four oncology-focused companies: Loch Lomond Therapeutics, Loch Eil Therapeutics, Loch Ness Therapeutics, and Llyn Bala Therapeutics. Carl Gordon, Iain Dukes, and Jim Sullivan from OrbiMed, along with Nikolay Savchuk from Torrey Pines Investment, have joined the boards of these four companies. The proceeds will fund clinical candidate development, supported by Molsoft LLC's AI and computer-aided drug design platform.PR Newswirei2020 Accelerator Invests in Developing Novel Highly-Specific Approaches to Treatment of Neurodegenerative Diseases Based on Previously Unrecognized Protein-Protein Interactionsi2020 Accelerator announced a collaboration with the University of Turku to fund research into novel treatments for neurodegenerative diseases and neuropathic pain. The program leverages scientific expertise from ChemDiv to target specific protein-protein interactions, aiming to develop non-addictive pain treatments and neuroprotectants. Future investment in a startup based on these results is contingent upon achieving specific collaboration milestones.